天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-054 天津红日药业股份有限公司 第九届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津红日药业股份有限公司（以下简称"公司"）第九届监事会第三次会议 于 2025 年 10 月 27 日在天津市武清开发区创业总部基地 B01 号楼公司会议室以 现场加通讯表决方式召开,会议通知于 2025 年 10 月 16 日以邮件、电话的方式发 出。会议应参加监事 3 人，实际参加会议的监事 3 人（其中以通讯表决方式出席 会议的监事为 2 人）。本次会议以通讯表决的监事分别为：监事会主席叶尚书女 士、监事李俊先生。公司部分高级管理人员列席了会议。本次会议召开符合《公 司法》等相关法律法规和《公司章程》《公司监事会议事规则》的有关规定。 会议由公司监事会主席叶尚书女士主持，参会监事投票表决通过如下议案： 一、审议通过《关于公司<2025 年第三季度季度报告>的议案》； 监事会认为：公司董事会编制及审议公司《2025 年第三季度报告》的程序 符合法律、行政 ...

Core Insights - Hongri Pharmaceutical reported a revenue of 1.354 billion yuan for Q3 2025, representing a year-on-year decline of 6.32% [1] - The net profit attributable to shareholders was 2.1329 million yuan, down 89.40% year-on-year [1] - Basic earnings per share stood at 0.001 yuan [1] Financial Performance - For the first three quarters, the company achieved a revenue of 4.149 billion yuan, a decrease of 6.59% compared to the previous year [1] - The net profit attributable to shareholders for the same period was 80.7629 million yuan, reflecting a year-on-year decline of 52.03% [1] - Basic earnings per share for the first three quarters were 0.03 yuan [1]

Financial Performance - Q3 2025 revenue was CNY 1,353,594,654.88, a decrease of 6.32% year-over-year[5] - Net profit attributable to shareholders was CNY 2,132,915.33, down 89.40% compared to the same period last year[5] - Basic earnings per share decreased by 85.71% to CNY 0.001[5] - Total operating revenue for the current period is approximately ¥4.15 billion, a decrease of 6.6% compared to ¥4.44 billion in the previous period[20] - Net profit for the current period is approximately ¥91.93 million, a decline of 52.2% from ¥192.40 million in the previous period[21] - Earnings per share (EPS) for the current period is ¥0.03, down from ¥0.06 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,758,345,758.27, a decline of 3.64% from the previous year[5] - The company reported a total asset of ¥10,758,345,758.27 as of September 30, 2025, down from ¥11,165,116,699.53 at the beginning of the period, indicating a decrease of approximately 3.65%[16] - Total liabilities decreased from ¥2,366,561,176.36 to ¥1,962,784,651.56, indicating a reduction of about 17%[18] - Total equity attributable to shareholders of the parent company is approximately ¥8.64 billion, slightly down from ¥8.64 billion in the previous period[19] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 536,836,636.49, an increase of 6.28%[5] - Cash flow from operating activities generated a net amount of approximately ¥536.84 million, an increase of 6.3% from ¥505.13 million in the previous period[22] - The ending cash and cash equivalents balance was $1.39 billion, up from $1.04 billion in the prior period[23] - The company reported a net increase in cash and cash equivalents of $113.02 million, contrasting with a decrease of $505.06 million in the previous period[23] Investments and Expenses - Investment income for the period was CNY -287.46 million, a decrease of 160.99% year-over-year[10] - Financial expenses decreased by 64.26% to CNY 10.05 million compared to the same period last year[10] - The company reported a decrease in research and development expenses to approximately ¥132.73 million, down from ¥154.10 million in the previous period[20] - The company’s long-term investments decreased from ¥12,964,808.38 to ¥10,160,633.03, a decline of approximately 21.5%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 96,308[12] - The total number of restricted shares increased to 265,626,359 from 240,731,655, with an addition of 24,894,704 shares during the period[14] - The company has not disclosed any related party relationships among the top shareholders[13] Tax and Fees - The company needs to pay a total of ¥33,838,200 for tax and late fees, which includes ¥25,166,000 in taxes and ¥8,672,200 in late fees[15] Other Financial Metrics - Other comprehensive income after tax for the current period is approximately -¥308.94 thousand, compared to -¥1.51 million in the previous period[22] - The company experienced a net foreign exchange loss of approximately -¥45.77 million, compared to -¥50.47 million in the previous period[21] - Net cash flow from investment activities was -$93.36 million, a decrease from -$160.19 million in the previous period[23] - Cash inflow from financing activities totaled $51.26 million, compared to $36.08 million in the prior period[23] - Total cash outflow from financing activities was $381.02 million, down from $886.19 million year-over-year[23] - The net cash flow from financing activities was -$329.76 million, an improvement from -$850.11 million in the previous period[23] Audit Status - The company has not audited its third-quarter financial report[24]

Market Overview - The medical consumables supply chain SPD sector increased by 0.41% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Jianfa Zhixin (301584) closed at 29.30, up 4.46% with a trading volume of 186,400 shares and a transaction value of 534 million [1] - Dajia Weikang (301126) closed at 11.75, up 3.07% with a trading volume of 53,500 shares and a transaction value of 62.22 million [1] - Jianmo Information (605186) closed at 19.55, up 2.68% with a trading volume of 17,200 shares and a transaction value of 33.43 million [1] - Other notable performers include Hefei China (603122) up 1.91%, Langma Information (300288) up 1.48%, and Seli Medical (603716) up 1.48% [1] Capital Flow - The SPD sector experienced a net outflow of 43.97 million from institutional investors, while retail investors saw a net inflow of 16.33 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Seli Medical (603716) had a net inflow of 12.83 million from institutional investors, but a net outflow of 12.61 million from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 5.24 million from speculative funds, but a net outflow of 5.91 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 2.37 million from speculative funds, while retail investors experienced a net outflow of 4.64 million [3]

截至6月30日，红日药业股东户数10.08万，较上期减少2.01%；人均流通股27160股，较上期增加 1.98%。2025年1月-6月，红日药业实现营业收入27.95亿元，同比减少6.72%；归母净利润7863.00万元， 同比减少46.95%。 资料显示，天津红日药业股份有限公司位于天津市武清开发区创业总部基地B01号楼，成立日期2000年 9月30日，上市日期2009年10月30日，公司主营业务涉及药品和医用医疗器械的研发、生产和销售。主 营业务收入构成为：中药配方颗粒及饮片57.27%，血必净注射液21.73%，药械智慧供应链20.14%，其 他(补充)0.86%。 10月16日，红日药业涨0.80%，成交额1.71亿元。两融数据显示，当日红日药业获融资买入额2119.93万 元，融资偿还1753.04万元，融资净买入366.89万元。截至10月16日，红日药业融资融券余额合计6.31亿 元。 分红方面，红日药业A股上市后累计派现11.16亿元。近三年，累计派现2.70亿元。 融资方面，红日药业当日融资买入2119.93万元。当前融资余额6.30亿元，占流通市值的5.54%，融资余 额低于近一年10% ...

Core Points - Hongri Pharmaceutical Co., Ltd. announced a self-inspection regarding tax matters, resulting in a tax payment of 25.166 million yuan and late fees of 8.6722 million yuan, totaling 33.8382 million yuan [2] - The total amount of tax and late fees paid represents approximately 43% of the company's net profit for the first half of 2025, which was 78.63 million yuan [2] - The company stated that the tax payment and late fees will be included in the 2025 current profit and loss, with the final impact on net profit to be determined by audited financial statements [2] Company Actions - The proactive self-inspection and tax payment reflect the company's commitment to compliant operations, despite the short-term pressure on performance [3] - The company aims to avoid potential risks associated with tax issues by addressing the matter promptly [3]

Core Viewpoint - The Fujian Provincial Medical Security Bureau has announced the credit rating of two pharmaceutical companies, Beijing Kangrengtang Pharmaceutical Co., Ltd. and Guizhou Sanli Pharmaceutical Co., Ltd., both rated as "general" due to their involvement in commercial bribery cases [1][4]. Company Ratings - Beijing Kangrengtang Pharmaceutical Co., Ltd. was found to have engaged in bribery amounting to 46,000 yuan from 2013 to 2015 to medical institution personnel [2][4]. - Guizhou Sanli Pharmaceutical Co., Ltd. was involved in a bribery case where approximately 120,000 yuan was given to medical institution doctors to promote the prescription of its product, a children's throat spray [2][4]. Rating Criteria - The credit rating is based on the criteria set forth in the "Medical Price and Procurement Credit Rating Discretionary Standards" (2020 version), which states that companies involved in bribery exceeding 10,000 yuan but less than 150,000 yuan are rated as "general" [2][4].

Group 1 - On September 17, Hongri Pharmaceutical experienced a decline of 1.28% with a trading volume of 202 million yuan, and the net financing buy was -7.32 million yuan [1] - As of September 17, the total margin balance for Hongri Pharmaceutical was 646 million yuan, with a financing balance of 645 million yuan, accounting for 5.55% of the circulating market value, which is below the 20th percentile level over the past year [1] - The company’s main business revenue composition includes 57.27% from traditional Chinese medicine formula granules and decoction pieces, 21.73% from Xuebijing injection, and 20.14% from smart supply chain for medical devices [1] Group 2 - As of June 30, the number of shareholders for Hongri Pharmaceutical was 100,800, a decrease of 2.01% from the previous period, while the average circulating shares per person increased by 1.98% to 27,160 shares [2] - For the first half of 2025, Hongri Pharmaceutical reported operating revenue of 2.795 billion yuan, a year-on-year decrease of 6.72%, and a net profit attributable to shareholders of 78.63 million yuan, down 46.95% year-on-year [2] - Since its A-share listing, Hongri Pharmaceutical has distributed a total of 1.116 billion yuan in dividends, with 270 million yuan distributed over the past three years [3]

Core Viewpoint - Hongri Pharmaceutical (300026.SZ) announced the need to pay back taxes and penalties totaling 33.83 million yuan, which will directly impact the net profit attributable to shareholders in 2025 [1] Group 1 - The company and its wholly-owned subsidiary are required to pay back taxes of 25.166 million yuan and late fees of 8.6722 million yuan, totaling 33.8382 million yuan [1] - The total amount has been fully paid and does not involve any administrative penalties [1] - The payment will be recorded in the 2025 financial results, affecting the net profit for that year [1]

Core Viewpoint - Hongri Pharmaceutical (300026.SZ) announced the need to pay back taxes totaling 25.166 million yuan and late fees of 8.6722 million yuan, amounting to a total of 33.8382 million yuan, which has been fully paid as of the announcement date, and this repayment does not involve any administrative penalties [1] Group 1 - The company and its wholly-owned subsidiary are required to repay taxes and late fees totaling 33.8382 million yuan [1] - The total amount includes 25.166 million yuan in taxes and 8.6722 million yuan in late fees [1] - The repayment has been completed as of the date of the announcement [1]